Forbes46%
First U.S. Patients Treated With Microrobotic Surgery For Alzheimer’s 20%
By Alex Knapp0%
5/6/2026, 9:00:16 AM
BS Summary: This article contains 27 faulty reasoning types, including Appeal to Authority, Optimism Bias, and Availability Heuristic, with Halo Effect as the most egregious example at 14.9% saturation with 169 hits. Analysis detected 1,850 faulty-reasoning hits from 1,132 analyzed words, generating a BS Score of 34.4% and a BS Rank of 20% (17,588 of 21,887 articles). This article is better (less manipulative) than 80.40% of the article peer group.
A clinical trial for the use of microrobots in treating Alzheimer’s disease kicked off with its first robotic-assisted procedure in human patients at Baptist Health in Jacksonville, Florida.
The first patient, treated on Thursday, had moderate Alzheimer’s disease–the dementia that leads to devastating memory loss and affects 7 million people in the U.S. alone–and confirmed abnormalities in their deep cervical lymph node region.
Two additional patients with moderate Alzheimer’s underwent the procedure on Monday.
Microrobot maker MMI (Medical Microinstruments Inc.) expects to ultimately enroll 15 patients and follow them for 12 months after their operations.
The goal of the surgery is to clear drainage pathways to the patients’ brains, helping their own lymphatic systems flush the toxins that scientists believe are hallmarks of the disease.
Alzheimer’s has long confounded researchers, and efforts to develop treatments for it have resulted in a graveyard of failures, but fixing the brain’s “plumbing” with surgeries or drugs has attracted increased attention recently.
This has left scientists viewing MMI’s wildly experimental operation (which Forbes profiled earlier this year) with a mix of skepticism and hope.
While MMI’s studies are very early stage, they build off reports from some 5,000 experimental surgeries performed in China and other Asian countries over the past five years that have shown remarkable, if largely anecdotal, results.
MMI, which has raised $220 million from investors that include Fidelity, Deerfield Management and RA Capital at a valuation around $500 million, designed robots that use the smallest surgical instruments in the world that can hold tiny needles the size of eyelashes and scissors and dilators roughly the width of a human hair.
That’s crucial because the lymph vessels in the neck that surgeons operate on can be as small as 0.2 millimeters in diameter (about as thick as two sheets of paper).
The company, which was founded in Italy in 2015, already sells its precision robots for nerve repair and clearing fluid buildup in the arms and legs caused by lymphedema.
It got the okay from the FDA in November to proceed with the Alzheimer’s study with a goal of first showing that the procedure is safe.
If the trial is successful, it hopes to begin a large-scale clinical trial with a few hundred patients later this year.
The first patient went home over the weekend, and, CEO Mark Toland says, was singing songs in the car there–a positive sign.
As Toland told Forbes: “These are the patients that really don’t have a treatment option now.
If they can get this procedure done and see the impact, it’s groundbreaking.”
Indian billionaire Dilip Shanghvi is doubling down on the United States.
Last week, the company he controls, Sun Pharmaceutical Industries, agreed to buy publicly traded women’s health company Organon in a deal valued at $11.8 billion.
Sun Pharma first entered the U.S. in 1998 with the acquisition of Caraco Pharmaceuticals; last year, it bought skin cancer drug company Checkpoint Therapeutics for $355 million.
In its latest fiscal year (ended March 31, 2025), the American market accounted for roughly one-third of its more than $6 billion in revenue.
With the purchase, Sun’s annual revenue will more than double to $12.4 billion, making it one of the world’s top 25 drugmakers–and tilting its business further to the U.S.
Shanghvi called the Organon deal “a significant opportunity” that can help the company create a “stronger and more diversified platform.”
Now 70 and one of the world’s wealthiest healthcare entrepreneurs (worth $25.8 billion), he started Sun Pharmaceuticals in 1983 with a $200 loan from his father.
“Our story is all about incremental growth,” he told Forbes in 2008.
“We’re not looking for big leaps; we prefer small jumps.”
Three people on a cruise ship have died and five more have been sickened, apparently from a hantavirus infection.
The ship, MV Hondias, left Argentina with 149 passengers and crew on April 1 for the Canary Islands, visiting other islands along the way.
It is currently traveling to dock in the Canary Islands, pending clearance.
Hantavirus infections, typically spread through contact with rodents like rats or mice, are relatively rare but can cause severe complications depending on the strain of the virus.
In the United States, the most common strain is hantavirus pulmonary syndrome, a severe flu-like illness.
In Europe and Asia, strains typically cause a hemorrhagic fever that can harm the kidneys.
There are currently no FDA-approved vaccines or treatments for these infections, though new research into hantavirus structures published earlier this year may provide keys to developing them.
While hantavirus is most commonly transmitted from rodents, there is one exception: a rare strain known as the Andes virus, found in South America, which can spread from person-to-person and has a 40% mortality rate.
The World Health Organization confirmed today that the outbreak on the cruise ship was the Andes virus.
An international team led by the public health agency is currently investigating the outbreak and evacuating and treating patients as needed.
Although concerning, the disease requires close contact to spread, making a major outbreak unlikely as health authorities work to contain it.
Kanvas Biosciences, which is creating microbiome-based treatments for cancer and other diseases, raised $48 million led by DCVC and Lion’s Capital with additional investment from the Gates Foundation and others.
That brings the Princeton, N.J.-based biotech’s total funding to $78 million at a valuation that Kanvas declined to disclose.
The company plans to use the funds to support ongoing phase 1 clinical trials for two of its drug candidates: one to treat colitis caused by cancer immunotherapies, and the other to treat refractory cancers in concert with other medicines.
(Forbes covered the company’s seed round in 2024.)
Microbiome-based treatments have faced uphill challenges over the past decade, with seemingly promising solutions failing in clinical trials.
Kanvas’s cofounder and CEO Matthew Cheng told Forbes that his company’s spatial imaging techniques should help.
The company has built what he likens to a “Google Maps” that can identify promising strains of gut bacteria that can act in concert with each other to improve patients’ health.
Kanvas can make pills that contain 145 bacterial strains, an order of magnitude higher than many treatments that contain fewer than 10, Cheng said.
These act as a less-risky alternative to a fecal transplant, he added, replacing a disordered microbiome with healthier gut bacteria.
While this has conventionally been used to treat infections from the bacteria C. difficile, scientists are now experimenting with a wide range of applications, including support for cancer treatment as well as inflammatory bowel disorder, diabetes and food allergies.
“We are convinced that we have developed a therapy that can simulate the immune system in a particular way to make cancer therapy more effective and probably safer at the same time,” he said.
Speakers
8speakers29%attributed speech802writer words
Voice mapSelect a segment to jump to its words
Selected voice
100%flagged-word coverageMatthew Cheng
125 attributed words38% of attributed speech69% writer coverage
Attribution is sentence-level. Pattern percentages are calculated only from words assigned to that voice.
Loading…
Loading…
Loading…
Loading…
Analysis
Hover over highlighted words in the article to view the associated bias or fallacy analysis.